Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 226 participants.

Also called NCT07797036

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 226 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07797036
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07797036. Randomized; no masking; primary purpose prevention. Start 2027-09-01 (anticipated); primary completion 2030-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
Condition
Gestational Diabetes Mellitus (GDM)
Intervention (Drug)
Semaglutide (Wegovy) weekly injection
Lead sponsor
University of Massachusetts, Worcester (class: other)

Record details

Record id
cardio:ct-nct07797036
Content hash
56cf97aefc5556ddcc828d8266a7d8a754bd6b7aadee9c769c46ce92044899cf